NanoViricides

NNVC

Market cap $40.5M

SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential treatment options for Ebola Bundibugyo virus strain and finds that the Company's broad-spectrum antiviral drug candidate NV-387 is worthy of evaluation in this scenario. The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source[1], such as fruit bats.

NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antiviral drug developer sold about 1.3 million shares of common stock, or pre-funded warrants in lieu of shares, along with accompanying warrants to purchase an additional roughly 1.3 million common shares.

SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced the closing of its previously announced registered direct offering (the "Offering") of 1,333,334 million shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares (the "Offering"). The Offering was made to a single, fundamental institutional investor and priced at-the-market price of US$1.50 for each common share and accompanying whole warrant to purchase one common share.

NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of Ebola virus that has prompted the World Health Organisation to declare a global health emergency. The WHO designated the outbreak in eastern Democratic Republic of Congo a Public Health Emergency of International Concern on 17 May, after the virus killed at least 88 people across 336 suspected cases, with two infections also confirmed in neighbouring Uganda.

SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387 as another severe Ebolavirus outbreak has occurred in the Eastern part of DR Congo (DRC), with spillage across the border into Uganda. "We believe NV-387 could be effective against the Bundibugyo strain of Ebola that is ravaging DRC," said Anil R.

NanoViricides (NYSE-A:NNVC) said it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately $2 million in a registered direct offering. Under the terms of the agreement, the company will sell just over 1.3 million common shares, or pre-funded warrants in lieu thereof, together with accompanying warrants to purchase an equal number of common shares.

SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 1,333,334 million common shares (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares for gross proceeds of approximately US$2 million in a registered direct offering (the "Offering"). The common shares are being sold in combination with an accompanying full warrant (with each whole warrant being exercisable into one common share of the Company).

SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2026 with the Securities and Exchange Commission (SEC) on Thursday, May 14, 2026.

NanoViricides (NYSE-A:NNVC) is pointing to its lead drug candidate NV-387 as a potential solution to a critical gap in infectious disease preparedness, as a deadly hantavirus outbreak aboard a cruise ship triggers a costly global containment effort. The Connecticut-based clinical-stage company said NV-387 has completed Phase I clinical trials for safety and tolerability in healthy volunteers and has shown effectiveness against multiple virus families in lethal animal models, including coronaviruses, RSV, influenza, monkeypox and measles, tested via the same respiratory route through which Andes hantavirus spreads.

SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387 in light of the recent Andes hantavirus incident on a cruise ship that has led to a flurry of worldwide activity to effectively quarantine the ship MV Hondius and trace passengers' contacts in an effort to prevent a potential global epidemic. "NV-387 could have possibly saved lives of the infected patients, given the preponderance of evidence on effectiveness of NV-387 in lethal lung infections in animal models," said Anil R.